Article ID Journal Published Year Pages File Type
5713737 American Journal of Otolaryngology 2017 8 Pages PDF
Abstract
Bevacizumab is associated with both septal perforation and more widespread sinonasal toxicity. These lesions tend to produce only mild symptoms and can usually be managed conservatively. The decision to hold bevacizumab therapy should be made in conjunction with the patient and medical oncologist. Otolaryngologists should be aware of the toxicity from this increasingly common oncologic therapy.
Related Topics
Health Sciences Medicine and Dentistry Otorhinolaryngology and Facial Plastic Surgery
Authors
, ,